Systematical evaluation of bone fusion rate after interbody fusion in patients with osteoporosis and lumbar degenerative disease treated with teriparatide

doi:10.12307/2022.990

Abstract

Abstract: OBJECTIVE: To systematically review the changes of bone fusion rate after interbody fusion in patients with osteoporosis and lumbar degenerative disease treated with teriparatide.
METHODS: A comprehensive search of PubMed, Embase, Cochrane library, Home-ClinicalTrials (US clinical trial database), CNKI, Wanfang, VIP, Chinese Biomedical Literature Service System and Chinese clinical trial database was performed with “teriparatide, spinal fusion, spondylodesis, randomized controlled trial, randomized, placebo” as English search terms and “teriparatide, spinal fusion, lumbar fusion, interbody fusion” as Chinese search terms. The search time was from database establishment to November 16, 2021. All randomized controlled trials of teriparatide after lumbar fusion in patients with osteoporosis and lumbar degeneration were collected. The methodological quality of the literature was analyzed using the Cochrane Review Manual. Primary outcome measures were the rate of bone fusion, the number of patients with pedicle screw loosening, and the rate of pedicle screw loosening. Secondary outcome measure was the Oswestry Disability Index score for low back pain at 12-month follow-up. Meta-analysis was performed using RevMan 5.3 and Stata 16.0 software.
RESULTS: (1) A total of 9 high-quality research articles were included, including 536 patients. (2) Meta-analysis results showed that bone fusion rate was significantly increased in the teriparatide group compared with the control group at 6-month follow-up [RR=1.96, 95%CI(1.38-2.80), Z=3.73, P=0.000 2 < 0.05], but there was no significant difference in bone fusion rate between teriparatide group and control group at 12-month follow-up [RR=1.02, 95%CI(0.88-1.17), Z=0.23, P=0.82 > 0.05], suggesting that teriparatide can improve postoperative bone fusion rate and shorten bone fusion time in osteoporotic patients with lumbar degenerative diseases. (3) At a follow-up time of 12 months, the loosening rate of pedicle screws in the teriparatide group was significantly lower than that in the control group (P < 0.05). (4) There was no significant difference in the number of pedicle screw loosening between the teriparatide group and the risedronate group [RR=0.99, 95%CI(0.58-1.70), Z=0.02, P=0.98 > 0.05], but the number of pedicle screw loosening could be significantly reduced in the teriparatide group compared with the risedronate group [RR=0.50, 95%CI(0.32-0.78), Z=3.05, P=0.002 < 0.05].
CONCLUSION: (1) Teriparatide can promote bone fusion and shorten bone fusion time. (2) Teriparatide can reduce the incidence of pedicle screw loosening. (3) The effect of teriparatide on postoperative low back pain Oswestry Disability Index score cannot be clarified.

Key words: teriparatide, osteoporosis, lumbar fusion, interbody fusion, meta-analysis, randomized controlled trial

CLC Number:

Jiang Xiaocheng, Shi Lu, Wang Yinbin, Li Qiujiang, Xi Chuangzhen, Ma Zefeng, Cai Lijun. Systematical evaluation of bone fusion rate after interbody fusion in patients with osteoporosis and lumbar degenerative disease treated with teriparatide[J]. Chinese Journal of Tissue Engineering Research, 2023, 27(9): 1427-1433.

Figures/Tables 17

References

[1] 朱洁云,高敏,宋秋韵,等.中国老年人骨质疏松症患病率的Meta分析[J].中国全科医学,2022,25(3):346-353.
[2] ALDINI NN, FINI M, GIAVARESI G, et al. Pedicular fixation in the osteoporotic spine: a pilot in vivo study on long-term ovariectomized sheep. J Orthop Res. 2002; 20(6):1217-1224.
[3] COE JD, WARDEN KE, HERZIG MA, et al. Influence of bone mineral density on the fixation of thoracolumbar implants. A comparative study of transpedicular screws, laminar hooks, and spinous process wires. Spine (Phila Pa 1976). 1990; 15(9):902-907.
[4] KAWAGUCHI Y. Genetic background of degenerative disc disease in the lumbar spine. Spine Surg Relat Res. 2018;2(2):98-112.
[5] CHEUNG KM, KARPPINEN J, CHAN D, et al. Prevalence and pattern of lumbar magnetic resonance imaging changes in a population study of one thousand forty-three individuals. Spine (Phila Pa 1976). 2009;34(9):934-940.
[6] DEYO RA, GRAY DT, KREUTER W, et al. United States trends in lumbar fusion surgery for degenerative conditions. Spine (Phila Pa 1976). 2005;30(12):1441-1445; discussion 1446-1447.
[7] KATZ JN. Lumbar spinal fusion. Surgical rates, costs, and complications. Spine (Phila Pa 1976). 1995;20(24 Suppl):78S-83S.
[8] HIRSCH BP, UNNANUNTANA A, CUNNINGHAM ME, et al. The effect of therapies for osteoporosis on spine fusion: a systematic review. Spine J. 2013;13(2): 190-199.
[9] OHTORI S, INOUE G, ORITA S, et al. Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study. Spine (Phila Pa 1976). 2012;37(23): E1464-1468.
[10] OHTORI S, INOUE G, ORITA S, et al. Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. Spine (Phila Pa 1976). 2013; 38(8):E487-492.
[11] 周晓清,陈晓钢,胡小吾,等.特立帕肽预防骨质疏松患者腰椎融合术后椎弓根螺钉松动的前瞻性研究[J].中国骨质疏松杂志,2014,20(3):285-287,296.
[12] EBATA S, TAKAHASHI J, HASEGAWA T, et al. Role of Weekly Teriparatide Administration in Osseous Union Enhancement within Six Months After Posterior or Transforaminal Lumbar Interbody Fusion for Osteoporosis-Associated Lumbar Degenerative Disorders: A Multicenter, Prospective Randomized Study. J Bone Joint Surg Am. 2017;99(5): 365-372.
[13] 刘汉辉,赵晓东,陈光福,等.腰椎滑脱伴骨质疏松症患者TLIF术后应用特立帕肽治疗的临床研究[J].中国当代医药, 2018,25(19):12-16.
[14] USHIROZAKO H, HASEGAWA T, EBATA S, et al. Weekly Teriparatide Administration and Preoperative Anterior Slippage of the Cranial Vertebra Next to Fusion Segment < 2 mm Promote Osseous Union After Posterior Lumbar Interbody Fusion. Spine (Phila Pa 1976). 2019;44(5):E288-E297.
[15] JESPERSEN AB, ANDRESEN ADK, JACOBSEN MK, et al. Does Systemic Administration of Parathyroid Hormone After Noninstrumented Spinal Fusion Surgery Improve Fusion Rates and Fusion Mass in Elderly Patients Compared to Placebo in Patients With Degenerative Lumbar Spondylolisthesis? Spine (Phila Pa 1976). 2019;44(3):157-162.
[16] BURCH S, TALIAFERRO K, BERVEN SH, et al. Assessment of the efficacy of teriparatide (Forteo) in patients undergoing posterolateral lumbar spinal fusion: a double-blinded randomized pilot study. Spine Journal. 2019; 19(9):S81.
[17] OBA H, TAKAHASHI J, YOKOMICHI H, et al. Weekly Teriparatide Versus Bisphosphonate for Bone Union During 6 Months After Multi-Level Lumbar Interbody Fusion for Osteoporotic Patients: A Multicenter, Prospective, Randomized Study. Spine (Phila Pa 1976). 2020;45(13):863-871.
[18] COMPSTON JE, MCCLUNG MR, LESLIE WD. Osteoporosis. Lancet. 2019;393(10169):364-376.
[19] 杨埜,陈金忠,李野,等.FRAX工具预测桂西地区2型糖尿病患者骨折风险的相关性分析[J].中国骨质疏松杂志,2020, 26(4):560-563,577.
[20] SOLDOZY S, SARATHY D, SKAFF A, et al. Pharmacologic considerations in patients with osteoporosis undergoing lumbar interbody fusion: A systematic review. Clin Neurol Neurosurg. 2020;196:106030.
[21] DRAKOPOULOS P, FLEVAS DA, GALANOPOULOS IP, et al. Off-Label Use of Teriparatide in Spine. Cureus. 2021;13(7): e16522.
[22] 林红,李泽方,孟俊融,等.特立帕肽与唑来膦酸对合并骨质疏松的腰椎融合术的患者骨代谢与骨融合的对比研究[C].武汉:2019楚天骨科高峰论坛暨第二十六届中国中西医结合骨伤科学术年会论文集, 2019.
[23] 孟俊融,姜允琦,李熙雷,等.骨质疏松症患者行腰椎融合术后使用特立帕肽与唑来膦酸的对比研究[C].呼和浩特:第二十四届中国中西医结合骨伤科学术年会论文汇编,2017.
[24] SAAG KG, PETERSEN J, BRANDI ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017;377(15):1417-1427.
[25] YOLCU YU, ZREIK J, ALVI MA, et al. Use of teriparatide prior to lumbar fusion surgery lowers two-year complications for patients with poor bone health. Clin Neurol Neurosurg. 2020;198:106244.
[26] SUGIURA T, KASHII M, MATSUO Y, et al. Intermittent administration of teriparatide enhances graft bone healing and accelerates spinal fusion in rats with glucocorticoid-induced osteoporosis. Spine J. 2015;15(2):298-306.